Defactinib
- Generic Name
- Defactinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21F3N8O3S
- CAS Number
- 1073154-85-4
- Unique Ingredient Identifier
- 53O87HA2QU
- Background
Defactinib has been investigated for the treatment of Malignant Pleural Mesothelioma.
- Associated Conditions
- -
- Associated Therapies
- -
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
- Conditions
- Interventions
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Clinical Hub for Interventional Research (CHOIR)
- Target Recruit Count
- 12
- Registration Number
- NCT05636514
- Locations
- 🇦🇺
Prince of Wales Hospital, Sydney, New South Wales, Australia
🇦🇺Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
🇦🇺Concord Repatriation and General Hospital, Sydney, New South Wales, Australia
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 42
- Registration Number
- NCT04331041
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Pembrolizumab + Defactinib In Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Raphael Bueno, MD
- Registration Number
- NCT04201145
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Phase I Trial of Defactinib and VS-6766.
- Conditions
- Interventions
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 87
- Registration Number
- NCT03875820
- Locations
- 🇬🇧
The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
🇬🇧The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
🇬🇧The Royal Marsden NHS Foundation Trust - Gynecology Unit, Sutton, United Kingdom
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2024-01-24
- Target Recruit Count
- 36
- Registration Number
- NCT03727880
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Samuel Oschin Cancer Center at Cedars-Sinai, Los Angeles, California, United States
A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT02913716
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
- Conditions
- Interventions
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2018-03-19
- Lead Sponsor
- NHS Greater Glasgow and Clyde
- Target Recruit Count
- 59
- Registration Number
- NCT02758587
- Locations
- 🇬🇧
Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom
🇬🇧Belfast Health and Social Care Trust, Cancer Centre, Lisburn Road, Belfast, United Kingdom
🇬🇧Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Conditions
- Interventions
- Drug: AfatinibDrug: CapivasertibDrug: BinimetinibDrug: AdavosertibProcedure: Biospecimen CollectionOther: Cytology Specimen Collection ProcedureDrug: Afatinib DimaleateDrug: DabrafenibDrug: DefactinibDrug: FexagratinibDrug: DasatinibDrug: IpatasertibProcedure: BiopsyDrug: CrizotinibDrug: Dabrafenib MesylateDrug: TaselisibDrug: SapanisertibDrug: PI3K-beta Inhibitor GSK2636771Drug: Defactinib HydrochlorideDrug: PalbociclibBiological: NivolumabDrug: CopanlisibDrug: UlixertinibBiological: Trastuzumab EmtansineDrug: Copanlisib HydrochlorideBiological: RelatlimabProcedure: Computed TomographyDrug: TrametinibBiological: PertuzumabDrug: ErdafitinibProcedure: Radiologic ExaminationProcedure: Multigated Acquisition ScanDrug: LarotrectinibProcedure: EchocardiographyDrug: OsimertinibBiological: TrastuzumabDrug: Larotrectinib SulfateOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingDrug: VismodegibDrug: Sunitinib MalateProcedure: Radionuclide Imaging
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6452
- Registration Number
- NCT02465060
- Locations
- 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸Katmai Oncology Group, Anchorage, Alaska, United States
Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies
- First Posted Date
- 2013-09-16
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01943292
- Locations
- 🇯🇵
Kinki University Hospital, Osaka, Japan
Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer
- First Posted Date
- 2013-01-29
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01778803
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸University of Oklahoma, Oklahoma City, Oklahoma, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.